Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons
Conditions: Epstein-Barr Virus Infection; Infectious Mononucleosis; Herpesvirus Interventions: Drug: Matrix-M1 Adjuvant; Drug: EBV gp350-Ferritin Vaccine; Other: Placebo Comparator Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Allergy | Allergy & Immunology | Glandular Fever (infectious mononucleosis) | Infectious Diseases | Research | Vaccines